[Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer].
During the recent congress of urology and oncology key topics discussed were the evolution of survival data in metastatic kidney cancer which median is now around 40 months, persistent questions about the role of nephrectomy, including access to the systemic treatment of nephrectomized patients and tumor resectability induced by systemic therapies, the emergence of new prognostic models which are adapted to new therapeutic standards, and the emergence of promising new drugs including pazopanib. This article describes these advances.
Patard
J-J
JJ
Service d'Urologie, CHU Pontchaillou, Rue Henri le Guillou, Rennes, France. jean-jacques.patard@univ-rennes1.fr
Escudier
B
B
Paparel
P
P
Neuzillet
Y
Y
Long
J-A
JA
Baumert
H
H
Correas
J-M
JM
Lang
H
H
Poissonnier
L
L
Rioux-Leclercq
N
N
Soulié
M
M
D003226:Congresses as Topic; D018450:Disease Progression; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D009362:Neoplasm Metastasis; D009392:Nephrectomy; D011379:Prognosis